Merck & Co Inc said on Friday that its experimental COVID-19 pill reduced the risk of hospitalization and death by 30% in one study, according to data from all patients enrolled in an advanced study.
The company said data on the drug molnupiravir, developed with Ridgeback Biotherapeutics, had been submitted to the U.S. Food and Drug Administration ahead of a meeting of its expert advisers on Tuesday.
A planned interim analysis of data last month showed that 7.3% of people who received molnupiravir twice a day for five days were hospitalized and none had died 29 days after treatment. This compares to a hospitalization rate of 14.1% for patients on placebo.
In the updated data, 6.8% of people who received molnupiravir were hospitalized and one person died, while the other placebo group had a hospitalization rate of 9.7%.